GLP-1 Demand Is Reshaping Peptide Manufacturing: Why...

The Scale of What Has Changed

The GLP-1 therapeutics class has undergone a commercial expansion without recent precedent in pharmaceutical manufacturing. Using bottom-up company-reported sales for the two dominant franchises — Novo Nordisk and Eli Lilly — and converting Novo Nordisk's Danish kroner figures using OECD/FRED annual average exchange rates, the combined class grew from an estimated $12.3 billion in 2020 to approximately $52.8 billion in 2024 and roughly $76.2 billion in 2025.

The trajectory is striking not only in magnitude but in acceleration. Top-line growth from $12B to $76B in five years implies a demand expansion that cascades through every layer of the manufacturing supply chain — from fill-finish capacity (the bottleneck that dominates public discussion) down through API synthesis, purification, raw material sourcing, and the coupling reagents consumed in peptide bond formation.

Market projections for 2030 vary significantly depending on definitional scope. A broad "GLP-1 analogues" definition yields published projections as high as $268 billion by 2030. Narrower obesity-drug market consensus from investment banks and industry analysts clusters closer to $95–105 billion, with earlier $150 billion targets being pushed toward 2035 as pricing pressure and oral entrants reshape the competitive landscape. For supply chain planning, the important insight is not which projection is correct but that even the conservative scenarios imply sustained, large-scale peptide manufacturing demand for the remainder of this decade.

Why Coupling Reagents Matter in This Story

The Chemistry of GLP-1 Production

The connection between GLP-1 demand and coupling reagent consumption is not abstract. It is driven by the specific chemistry of how these molecules are made.

Semaglutide (MW 4113.58 g/mol): The FDA label states that the peptide backbone is produced by yeast fermentation, followed by chemical modification. The EMA assessment confirms production via recombinant yeast followed by chemical modifications, describing a large chemical moiety — a C18 fatty di-acid attached via a hydrophilic spacer to lysine 26 — that enables albumin binding and extended half-life. This lipidation step is an amide bond formation that is directly relevant to coupling reagent selection.

Tirzepatide (MW 4813.53 Da): The FDA label describes a 39-amino-acid modified peptide with a C20 fatty di-acid moiety attached via a linker to a lysine residue. The fatty-acid attachment is again a chemical modification step where coupling reagent choice affects hydrolysis rates, over-acylation risk, and downstream purification burden.

In both cases, regardless of whether the peptide backbone is produced biosynthetically or by SPPS, there is at least one quality-critical chemical amidation step — and in many manufacturing scenarios, multiple coupling steps across the overall process. Coupling reagent performance at these steps directly influences impurity profiles, yields, and ultimately the cost of goods.

Consumption at Scale

A straightforward consumption model illustrates why this matters commercially. For a semaglutide-like molecule at 2,000 kg API output per year, with DMTMM used for a single lipidation step at 1.5 equivalents and 0.9 yield factor, the estimated DMTMM chloride consumption is approximately 224 kg per year. With DMTMM·BF₄, that figure rises to approximately 266 kg; with DMTMM·PF₆, approximately 313 kg — reflecting the higher molecular weights of the alternative salt forms.

For a tirzepatide-like molecule under the same assumptions, the figures are approximately 192 kg (Cl), 228 kg (BF₄), and 269 kg (PF₆) per year.

These numbers reflect single-step adoption. If DMTMM were adopted for multiple SPPS couplings — even selectively for difficult positions — the demand scales dramatically. An illustrative scenario with 30 SPPS couplings at 500 kg API per year using DMTMM chloride at 3.0 equivalents yields an estimated 16,800 kg per year of reagent consumption.

The practical reality falls between these extremes. Most manufacturers will adopt a new coupling reagent for specific quality-critical steps rather than replacing their entire reagent toolkit. But even conservative single-step adoption, multiplied across the growing number of GLP-1 manufacturing campaigns globally, produces substantial aggregate demand.

The Bottleneck Has Moved

From Fill-Finish to Chemistry

The public conversation about GLP-1 manufacturing constraints has focused heavily on fill-finish capacity — the final manufacturing step where API is formulated into injectable devices. Novo Nordisk has reported periodic supply constraints and continued investment in internal and external capacity. Eli Lilly's public filings describe broad manufacturing network investments and ongoing facility expansion.

These investments are real and important. But they have shifted attention away from a more fundamental constraint that is now surfacing: the chemistry itself. As manufacturing volumes scale, process decisions that were adequate at clinical-scale production — reagent choices optimized for speed in early programs, impurity management approaches that relied on small-scale purification capacity — become cost and throughput constraints at commercial scale.

Three Decisions Moving Earlier

High-performing manufacturing organizations are responding by moving three categories of decisions earlier in the development timeline:

Reagent resilience. Process teams are evaluating coupling reagents not only on reaction performance but on supply depth and alternative sourcing. A reagent that provides excellent yields but is available from a single source with limited capacity creates a supply chain risk that compounds at commercial scale. The investment and capacity expansion signals from major peptide CDMOs — CordenPharma's approximately €900 million peptide and GLP-1 investment, WuXi TIDES tripling peptide capacity — create repeated qualification windows where procurement teams assess reagent supply robustness alongside chemical performance.

Purification economics. Coupling reagent selection affects not just the reaction step but the entire downstream purification train. Impurity profiles generated during amide bond formation — urea derivatives from carbodiimides, guanidinylation products from uronium reagents, triazine-derived byproducts from DMTMM — differ qualitatively in their chromatographic behavior, toxicological significance, and removal difficulty. At commercial scale, a reagent that produces harder-to-remove impurities at slightly lower concentration can be more expensive overall than a reagent with somewhat lower conversion but cleaner impurity profile.

Route optionality. Manufacturing organizations that lock into a single reagent system during development may face costly revalidation if that reagent becomes constrained, if the impurity profile proves problematic at scale, or if regulatory changes affect acceptable residual limits. Preserving realistic fallback conditions — qualifying at least two coupling approaches for quality-critical steps — provides negotiation leverage with both CDMOs and internal manufacturing groups and reduces the risk of late-stage surprises during tech transfer.

ICH Q7 and the Qualification Cascade

For pharmaceutical manufacturing, the coupling reagent is not just a reaction input — it is a controlled material subject to ICH Q7 supplier change control requirements. Changing a coupling reagent after process validation triggers regulatory documentation updates, comparative impurity profiling, and potentially additional stability studies. The cost and timeline implications of post-validation reagent changes provide a strong incentive to make deliberate, well-characterized reagent selections during development rather than defaulting to whatever was in the lab when the project started.

This regulatory framework means that reagent qualification decisions made in early development have multi-year commercial consequences. A manufacturer that qualifies DMTMM alongside a legacy reagent during development retains flexibility; one that reaches Phase 3 with a single qualified coupling system has limited options if supply disruption or scale-dependent impurity issues emerge.

Why This Matters Beyond GLP-1

The structural lessons from the GLP-1 cycle are not specific to semaglutide or tirzepatide. They apply to any high-volume peptide program — and the pipeline is deepening. Multiple companies are advancing GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and related incretin-pathway molecules through clinical development. Beyond GLP-1, peptide-based programs in oncology, metabolic disease, and rare disease continue to advance, each carrying their own manufacturing-scale coupling reagent requirements.

The key insight is that coupling chemistry has historically been treated as a lab-level tactical decision. The GLP-1 scale-up experience is demonstrating that it is actually a manufacturing-level strategic decision with direct impact on cost of goods, supply chain resilience, regulatory flexibility, and timeline risk.

The CDMO Investment Cascade

The manufacturing expansion is not limited to Novo Nordisk and Eli Lilly's internal facilities. The CDMO sector — where many GLP-1 programs are manufactured under contract — is investing at a scale that creates structural demand for all process inputs, including coupling reagents.

CordenPharma has committed approximately €900 million in peptide and GLP-1 related manufacturing investment. WuXi TIDES has announced plans to triple its peptide manufacturing capacity, with GLP-1 programs cited as a primary demand driver. These are not speculative commitments — they represent physical plant construction, equipment procurement, and process validation programs that will consume raw materials, reagents, and analytical standards at scale.

Each facility expansion triggers supplier qualification activity. When a CDMO brings new reactor capacity online, every critical raw material — including coupling reagents — must be re-qualified in the new equipment. This creates a recurring window for process teams to evaluate alternative reagents, including DMTMM, against their incumbent systems. The qualification burden that normally discourages reagent switching is temporarily reduced during facility commissioning, making these expansion cycles the highest-probability entry points for new reagent adoption.

For DMTMM specifically, the SPPS literature provides a documented entry point: published comparisons showing DMTMM as an economical alternative to PyBOP with comparable yields under evaluated conditions. The aqueous amidation literature — particularly the systematic comparison on hyaluronan functionalization showing DMTMM's superiority over EDC/NHS without tight pH control (D'Este et al., AO Foundation) — provides a second entry vector for lipidation and linker-attachment chemistry where aqueous compatibility matters.

ICH Q7 and the Regulatory Dimension

Under ICH Q7 guidelines for active pharmaceutical ingredient GMP, coupling reagents used in the synthesis of pharmaceutical peptides are classified as controlled materials. Supplier changes for controlled materials require documented change control procedures, comparative testing, and potentially regulatory notification depending on where in the synthesis the reagent is used and the stage of the product lifecycle.

This regulatory framework has a counterintuitive effect on reagent strategy. It raises the cost of changing reagents after process validation, which should motivate teams to evaluate reagent options more thoroughly during development. In practice, many teams do the opposite — they default to familiar reagents during development to avoid early-stage complexity, then discover during tech transfer that their reagent choice creates cost, supply, or impurity problems at manufacturing scale.

The GLP-1 experience is correcting this pattern for the organizations paying attention. Teams that qualify multiple reagent options during development — including both a primary and a fallback coupling system for quality-critical steps — maintain operational flexibility that becomes increasingly valuable as manufacturing volumes grow and supply chain disruption risk compounds.

Evidence Limits to Acknowledge

• Market size figures are estimates derived from company-reported sales and third-party projections. They should be used for directional planning, not precise forecasting.
• The consumption model is scenario-based and uses illustrative parameters. Actual demand depends on specific process conditions, stoichiometry choices, and yield factors that vary by manufacturer.
• DMTMM's positioning as an "economical alternative to PyBOP" in SPPS is based on published comparative data in specific model systems. Transferability to GLP-1 manufacturing processes requires process-specific validation.
• The shift toward oral GLP-1 candidates (non-peptide small molecules) may reduce long-term peptide API demand growth, partially offsetting the scaling trend described here. The timing and magnitude of this effect are uncertain.
• CDMO investment figures are publicly reported announcements and may not reflect final capital deployment.

The Strategic Takeaway

If your peptide program still treats coupling chemistry as a late optimization task — something to revisit during tech transfer after the molecule has advanced through clinical development — the GLP-1 experience is your case study for why that approach fails at scale.

The organizations navigating this expansion most effectively are the ones that built reagent strategy into their platform thinking from the beginning. They qualified multiple coupling approaches during development. They characterized impurity profiles under manufacturing-relevant conditions rather than lab-scale approximations. They evaluated reagent suppliers on capacity and documentation quality, not just catalog pricing.

For everyone else, the GLP-1 cycle is an opportunity to update the playbook before the next high-volume peptide program reaches the same inflection point. The specific molecules will change — oral formulations, next-generation dual and triple agonists, and entirely new peptide-based therapeutic modalities will each bring their own manufacturing requirements. But the structural lesson will not change: coupling chemistry is a manufacturing-level strategic decision, not a lab-level tactical convenience. The organizations that internalize this now will build process platforms that absorb future demand shocks without sacrificing quality, timeline, or margin.

Upstream choices now determine whether scale-up feels like execution or recovery.